In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president and head ...

The Centers for Medicare & Medicaid Services (CMS) has proposed two more programmes in the Trump administration's efforts to ...

People in life sciences companies understand how patents are crucial to their business, by setting competitive boundaries, ...

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of an oral formulation of ...

But the digital-first promise carried a blind spot: it solves for tasks, not emotions. Patients don’t start, stay on, or ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, his personal motivations rooted in patient impact, and his perspective on ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials. The conversation touches upon how large language models ...

A first-of-its-kind partnership between medicines regulators in the UK and Singapore could allow patients in both countries to access new medical advances more quickly. The UK's Medicines and ...

Whilst most of those working in the pharmaceutical industry have felt the pressures of rising costs and thinning pipelines over the last twenty years, some entrepreneurial souls have managed to turn a ...

Dr Peter Clardy, lead for the Google for Health Clinical Enterprise Team, speaks at the Google-EVERSANA event on Friday. Editor's Note: pharmaphorum is an editorially independent publication owned by ...